Anna Protopapas, Mersana CEO
In $1.36B biobuck deal with GSK, Mersana touts 'biggest preclinical ADC deal ever'
Days after Enhertu reeled in another FDA nod, with the first-ever green light for HER2-low breast cancer, another antibody drug conjugate biotech claims it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
